Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 89

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 89
---
Nan-Mupirocin formulation has indicated that this novel approach may allow for a new potent therapy to combat bacteria listed as serious
and urgent threats by the Center for Disease Control (CDC), subject to clinical trials. Management believes that the novel formulation
of Nano-Mupirocin may hold the potential to serve as a highly potent systemic therapy for serious life-threatening infections, such as
resistant Gonorrhea, MRSA induced endocarditis, or sepsis.

Key facts about mupirocin and findings from
preclinical research on Nano-Mupirocin:

| - | Broad antibacterial activity. The                                                                 
 antibacterial spectrum of mupirocin is well studied. Mupirocin is registered as a topical         
 ointment (Bactroban™ by GlaxoSmithKlein). Mupirocin is known to be highly effective               
 against staphylococci, streptococci, certain Gram-negative bacilli, including N. gonorrhoea       
 and a broad range of Gram-positive bacteria. [1] Mupirocin’s activity is enhanced at              
 acidic pH levels and is not significantly influenced by inoculum size, although its effectiveness 
 decreases in serum due to high protein binding (95%). Its primary mechanism involves inhibiting   
 RNA and protein synthesis by targeting the isoleucine-binding site on the isoleucyl-transfer-RNA  
 synthetase enzyme in bacteria. This unique mode of action, different from other antibiotics,      
 reduces the likelihood of cross-resistance.[2]                                                    |

| - | Spectrum and cellular uptake: Pre-clinical                                                          
 studies have indicated that Nano-Mupirocin has demonstrated a high level of tolerance, including    
 activity against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant           
 Enterococcus faecium (VRE), and cephalosporin-resistant Neisseria gonorrhoeae [3]. This formulation 
 indicated enhanced uptake by phagocytic cells such as macrophages and neutrophils, potentially      
 improving intracellular antibiotic delivery and bactericidal activity [4].                          |

| - | No cross-resistance: Due to                                                                      
 its unique mechanism, mupirocin does not display cross-resistance with β-lactams, glycopeptides, 
 or other classes of antibiotics, making it valuable in treating resistant strains [2].           |

| - | Preclinical profile: Nano-Mupirocin                                                            
 formulations appeared to be well